宁波市江北区≥60岁人群流感病毒裂解疫苗安全性监测  

Safety monitoring of split-virion influenza vaccine in people aged 60 and above in Jiangbei District,Ningbo City

作　　者：李萍萍[1] 张冰凌 叶莉霞[3] 吴一峰[1] LI Pingping;ZHANG Bingling;YE Lixia;WU Yifeng(Jiangbei District Center for Disease Control and Prevention,Ningbo,Zhejiang 315020,China;不详)

机构地区：[1]宁波市江北区疾病预防控制中心,浙江宁波315020 [2]宁波市江北区庄桥街道社区卫生服务中心 [3]宁波市疾病预防控制中心

出　　处：《中国预防医学杂志》2024年第2期234-238,共5页Chinese Preventive Medicine

基　　金：宁波市江北区科技计划项目(2020C01)。

摘　　要：目的监测分析在宁波市江北区≥60岁人群中接种三价流感病毒裂解疫苗(trivalent influenza splitvirion vaccine,TIV)和四价流感病毒裂解疫苗(quadrivalent influenza split-virion vaccine,QIV)的疑似预防接种异常反应(adverse events following immunization,AEFI)发生率。方法选择2020年9月—2021年4月在宁波市江北区预防接种门诊接种流感病毒裂解疫苗并符合纳入标准的研究对象,采用主动监测方式收集接种后30 d内发生的AEFI,分析AEFI发生率。结果宁波市江北区≥60岁人群流感病毒裂解疫苗发生AEFI409例(33.39‰),其中一般反应、异常反应、偶合症分别为389例(31.76‰)、11例(0.90‰)、9例(0.73‰)。TIV、QIV的AEFI发生率分别为34.34‰、29.58‰,差异无统计学意义(χ^(2)=1.366,P=0.257);TIV、QIV一般反应分别为32.81‰、27.53‰,差异无统计学意义(χ^(2)=2.456,P=0.117);异常反应分别为0.82‰、1.23‰,差异无统计学意义(χ^(2)=0.056,P=0.812)。TIV(χ^(2)=16.441,P<0.01)、QIV(χ^(2)=5.354,P=0.021)的AEFI发生率均为女性高于男性,差异有统计学意义;60~<70岁人群TIV的AEFI发生率低于70~<80岁和≥80岁,差异有统计学意义(χ^(2)=7.655、6.164,P=0.006、0.016),三个年龄组QIV的AEFI发生率差异无统计学意义(χ^(2)=0.975,P=0.601)。结论TIV和QIV在≥60岁人群中AEFI发生率较低,症状通常较轻微,具有良好的安全性。Objective To monitor and analyze the incidence of suspected Adverse Events Following Immunization(AEFI)after vaccination with trivalent influenza split-virion vaccine(TIV)and quadrivalent influenza split-virion vaccine(QIV)in the population aged 60 and above in Jiangbei District of Ningbo City.Methods All observation subjects who received split-virion influenza vaccine in various vaccination clinics in Jiangbei District of Ningbo City from September 2020 to April 2021 and met the inclusion criteria were selected.Active monitoring was used to collect AEFI within 30 days after vaccination,and the incidence of AEFI was analyzed.Results There were 409 cases(33.39%)of AEFI with split-virion influenza vaccine in the populations aged 60 and above,among which 389 cases(31.76%o)of common reactions,11 cases(0.90%o)of abnormal reactions,and 9 cases(O.73%o)of coincidental events.The incidence of TIV and QIV AEFI were 34.34%o and 29.58%o,respectively,with no statistically significant difference(χ^(2)=1.366,P=0.243),and the general reaction was 32.81%o and 27.53%o,respectively,with no statistically significant difference(χ^(2)=2.456,P=0.117).The abnormal reactions were 0.82%o and 1.23%o,respectively,and there was no significant difference(χ^(2)=0.056,P=0.812).The incidence of AEFI was higher in females than in males,and the difference was statistically significant(χ^(2)=16.441,P<0.01;χ^(2)=5.354,P=0.021),the incidence of AEFI in TIV aged 60 to<70 years was lower than that in TIV aged 70 to<80 years and≥80 years,and the difference was statistically significant(χ^(2)=7.609,P=0.006;χ^(2)=6.126,P=0.013);there was no significant difference in the incidence of AEFI in QIV among three age groups(χ^(2)=0.975,P=0.614).Conclusions TIV and QIV have a low incidence of AEFIin people aged 60 and above,and the symptoms are usually mild,indicating good safety.

关 键 词：流感病毒裂解疫苗 预防接种异常反应 安全性评价 

分 类 号：R186[医药卫生—流行病学]